Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 08:37:52 +0200Wed, 03 Apr 2024 13:05:00 +0200Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 14, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/yuflymaHuman medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 14, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/yuflymaWed, 03 Apr 2024 13:05:00 +0200Human medicineYuflyma : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5188_en.pdfYuflyma : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5188_en.pdfWed, 03 Apr 2024 13:01:00 +0200Human medicine